Boeck S - Search Results

1

Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts.

Westphalen CB, Preinfalk A, Kruger S, Haas M, Renz BW, Riener MO, Weber A, Kirchner T, Werner J, Heinemann V, von Bergwelt-Baildon M, Baba HA, Siveke JT, Ormanns S, Boeck S. Westphalen CB, et al. Among authors: boeck s. Clin Transl Oncol. 2019 Aug;21(8):1108-1111. doi: 10.1007/s12094-018-02030-6. Epub 2019 Jan 3. Clin Transl Oncol. 2019. PMID: 30607794

2

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer.

Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Boeck S, et al. Oncology. 2006;70(4):255-64. doi: 10.1159/000094888. Epub 2006 Aug 4. Oncology. 2006. PMID: 16899980 Free article. Review.

3

Importance of performance status for treatment outcome in advanced pancreatic cancer.

Boeck S, Hinke A, Wilkowski R, Heinemann V. Boeck S, et al. World J Gastroenterol. 2007 Jan 14;13(2):224-7. doi: 10.3748/wjg.v13.i2.224. World J Gastroenterol. 2007. PMID: 17226900 Free PMC article. Review.

4

Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?

Boeck S, Schulz C, Stieber P, Holdenrieder S, Weckbach S, Heinemann V. Boeck S, et al. Onkologie. 2007 Feb;30(1-2):39-42. doi: 10.1159/000097764. Epub 2007 Jan 26. Onkologie. 2007. PMID: 17264524 Free article.

5

Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.

Boeck S, Hausmann A, Reibke R, Schulz C, Heinemann V. Boeck S, et al. Anticancer Drugs. 2007 Oct;18(9):1109-11. doi: 10.1097/CAD.0b013e3281ceabec. Anticancer Drugs. 2007. PMID: 17704662

6

Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.

Boeck S, Wollenberg A, Heinemann V. Boeck S, et al. Ann Oncol. 2007 Sep;18(9):1582-3. doi: 10.1093/annonc/mdm420. Ann Oncol. 2007. PMID: 17761714 Free article. No abstract available.

7

The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis.

Boeck S, Ankerst DP, Heinemann V. Boeck S, et al. Oncology. 2007;72(5-6):314-21. doi: 10.1159/000113054. Epub 2008 Jan 14. Oncology. 2007. PMID: 18187951 Review.

8

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.

Boeck S, Heinemann V. Boeck S, et al. Future Oncol. 2008 Feb;4(1):41-50. doi: 10.2217/14796694.4.1.41. Future Oncol. 2008. PMID: 18240999 Review.

9

Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.

Boeck S, Heinemann V. Boeck S, et al. J Clin Oncol. 2008 Mar 1;26(7):1178-9; author reply 1179. doi: 10.1200/JCO.2007.15.3304. J Clin Oncol. 2008. PMID: 18309957 No abstract available.

10

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Heinemann V, et al. Among authors: boeck s. BMC Cancer. 2008 Mar 28;8:82. doi: 10.1186/1471-2407-8-82. BMC Cancer. 2008. PMID: 18373843 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

170 results

Search Page